Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04916821
Other study ID # 00001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 15, 2021
Est. completion date August 15, 2021

Study information

Verified date June 2021
Source Trabzon Kanuni Education and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary purpose: To investigate the effect of propolis, a food supplement product, on healing parameters in patients with COVID 19. Secondary purpose: To provide a new supportive treatment in Covid 19 treatment. In the present study to examine the effect of the use of propolis on healing parameters (laboratory and imaging) in patients with COVID 19; Propolis, which has antiviral properties, has also been used in humans in the COVID19 pandemic as of 2020. However, in these studies, an alcohol-soluble extract of propolis was used. Despite the disadvantages of its use in alcohol, it is clear that water and olive oil extracts of Propolis are safer for humans. Therefore, water extracts of propolis will be used in the study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 45
Est. completion date August 15, 2021
Est. primary completion date July 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 59 Years
Eligibility Inclusion Criteria: - Patients over the age of 18 who do not need a ventilator who are inpatient in the Covid service - Patients under the age of 60 who do not need a ventilator who are inpatient in the Covid service Exclusion Criteria: - patients do not have oral intake - patients whose informed consent form is not approved - patients who need a ventilator - pregnant women - children

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
propolis
Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules

Locations

Country Name City State
Turkey Trabzon Faculty of Medicine , Health Science University Trabzon

Sponsors (1)

Lead Sponsor Collaborator
Trabzon Kanuni Education and Research Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Berretta AA, Silveira MAD, Cóndor Capcha JM, De Jong D. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19. Biomed Pharmacother. 2020 Nov;131:110622. doi: 10.1016/j.biopha.2020.110622. Epub 2020 Aug 17. Review. — View Citation

Lima WG, Brito JCM, da Cruz Nizer WS. Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2). Phytother Res. 2021 Feb;35(2):743-750. doi: 10.1002/ptr.6872. Epub 2020 Sep 18. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary radiological Lung tomography findings Change from Baseline Lung Tomography Findings(Peripheral ground-glass opacities) at one week
Primary laboratory parameters-2: ESR ESR Change from Baseline ESR findings at one week
Primary laboratory parameters-3: CRP CRP Change from Baseline CRP findings at one week
Primary laboratory parameters-4: D-Dimer D-Dimer Change from Baseline D-Dimer findings at one week
Primary laboratory parameters-5: Troponin Troponin Change from Baseline Troponin findings at one week
Primary laboratory parameters-6: sO2 sO2 Change from Baseline sO2 findings at one week
Primary laboratory parameters-1: CBC CBC Change from Baseline CBC findings at one week
See also
  Status Clinical Trial Phase
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Recruiting NCT05311410 - Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures N/A
Active, not recruiting NCT05073718 - SARS-CoV-2 and Acetylsalicylic Acid (SARA) Phase 3
Completed NCT05060510 - The School SPIT Study - COVID-19 Testing in Secondary Schools N/A
Completed NCT05055492 - The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions N/A
Completed NCT05055505 - The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions N/A
Completed NCT05054218 - COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Completed NCT05449392 - Topical Antibacterial Agents for Prevention of COVID-19 Phase 1
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT05172024 - Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
Terminated NCT05593770 - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Phase 2/Phase 3
Completed NCT05030974 - RECOVAC Repeated Vaccination Study Phase 4
Withdrawn NCT05067946 - Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines Phase 2/Phase 3
Not yet recruiting NCT05013034 - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Phase 2
Withdrawn NCT05393999 - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations Phase 2
Recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Not yet recruiting NCT05116657 - Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
Recruiting NCT04590222 - Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Completed NCT04551911 - Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 Phase 2
Completed NCT04953039 - Use of Saliva for COVID-19 Diagnosis